Abstract
Purpose
Metastatic cancer of unknown primary origin is a syndrome characterised by a poor prognosis, with a typical survival rate from diagnosis of no longer than 1 year. Only 20–27% of primary tumours are identified by conventional radiological imaging. By contrast, it has been reported that 18F-fluorodeoxyglucose positron emission tomography (FDG PET) allows the identification of 24–40% of otherwise unrecognised primary tumours. To our knowledge, the studies on this topic have been conducted using 18F-FDG PET imaging alone. The aim of this study was to evaluate the potential additional diagnostic role of fused 18F-FDG PET-CT imaging for the detection of metastatic occult primary tumours.
Methods
The study population consisted of 21 consecutive patients with biopsy-proven metastatic disease and negative conventional diagnostic procedures. Each patient underwent a PET scan, carried out according to a standard procedure (6 h of fasting, i.v. injection of 370 MBq of 18F-FDG and image acquisition with a dedicated PET-CT scanner for 4 min per bed position).
Results
18F-FDG PET-CT detected the occult primary tumour in 12 patients (57% of cases), providing a detection rate higher than that reported with any other imaging modality, including conventional 18F-FDG PET.
Conclusion
The favourable results of this study need to be confirmed in larger patient populations with long-term follow-up.
This is a preview of subscription content, log in via an institution to check access.
References
Abbruzzese J, Abbruzzese M, Lenzi R, Hess K, Raber M. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995;13:2094–110.
Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, et al. Early metastatic cancer of unknown primary origin at presentation. Arch Intern Med 1988;148:2035–9.
Didolkar MS, Fanous N, Elias EG, Moore RH. Metastatic carcinoma from occult primary tumors: a study of 254 patients. Ann Surg 1977;186:625–30.
Steckel RJ, Kagan AR. Diagnostic persistence in working up metastatic cancer with an unknown primary site. Radiology 1980;134:367–9.
Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? A hypothesis. Med Hypotheses 2002;59:357–60.
Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 1990;66:1461–7.
Raber MN, Faintuch J, Abbruzzese JL, Sumrall C, Frost P. Continuous infusion 5-fluorouracil, etoposide and cisplatin in patients with metastatic carcinoma of unknown primary origin. Ann Oncol 1991;2:519–20.
Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160–6.
Alberini JL, Belhocine T, Hustinx R, Daenen F, Rigo P. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun 2003;24:1081–6.
Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816–22.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nanni, C., Rubello, D., Castellucci, P. et al. Role of 18F-FDG PET–CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 32, 589–592 (2005). https://doi.org/10.1007/s00259-004-1734-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-004-1734-3